

REMARKS

The specification has been amended in order to provide the appropriate cross-reference to related application information as well as an abstract.

Claims 1-5, 9-13, and 23-24, which are directed to the subject matter which was elected for prosecution and allowed in application Serial No. 09/857,882, and claims 6-8, which are directed to the subject matter which was elected for prosecution and allowed in application Serial No. 10/175,126, have been canceled.

Claims 14-17 and 21 have been amended in order to write these claims in the appropriate U.S. claim format.


Claims 18-20 and 22 have been canceled by the foregoing amendments.

New claims 25-28 have been added by the foregoing amendments. Support for new claims 25-28 occurs, for example, in original claims 18, 19, 20 and 22 respectively.

Claims 1-22 were in the application as filed. Claims 1-13, 18-20, and 22-24 were canceled and claims 25-28 were added by the instant amendment. Claims 14-17, 21, and 25-28 remain in the application.

Respectfully submitted,

Dated: 12/4/03


Michael D. Alexander
Registration No. 36,080

Address:
Sanofi-Synthelabo Inc.
Patent Department
9 Great Valley Parkway
Malvern, PA 19355
Tel.: (610) 889-8802
Fax: (610) 889-8799